E Kempf1,2, G Desamericq3,4,5,6, B Vieites7, I Diaz-Padilla8, E Calvo1, P Estevez1, A Garcia-Arreza9, M A Martinez-Maestre9, I Duran10,11. 1. Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain. 2. Medical Oncology Department, AP-HP, H. Mondor-A. Chenevier Hospital, Créteil, France. 3. Centre de Référence Maladie de Huntington, AP-HP, Hôpital H. Mondor-A. Chenevier, Créteil, France. 4. Inserm, U955, Equipe 01, Créteil, France. 5. Faculté de Médecine, Université Paris Est, Créteil, France. 6. Département d'Etudes Cognitives, Ecole Normale Supérieure, Paris, France. 7. Department of Pathology, Hospital Universitario Virgen del Rocio, Seville, Spain. 8. Deanery of Doctorate Studies, School of Medicine, University of Seville, Seville, Spain. 9. Gynecology Department, Hospital Universitario Virgen del Rocio, Seville, Spain. 10. Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain. ignacioduranmartinez@gmail.com. 11. Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain. ignacioduranmartinez@gmail.com.
Abstract
PURPOSE: Non-epithelial ovarian cancers (NEOCs) are rare diseases. Despite their overall good prognosis, the best management and current prognostic factors remain unclear. The objective of our study was to assess the clinical and pathological features of NEOC patients treated in our institution in the last 15 years and to explore risk factors for relapse and survival. METHODS/PATIENTS: All patients with a pathological diagnosis of NEOC referred to the medical oncology department at Hospital Universitario Virgen del Rocio between 1999 and 2014 were included. Demographics, tumor characteristics, treatment procedures, and clinical follow-up were retrospectively collected. Risk factors for disease-free survival (DFS) and overall survival (OS) were assessed. RESULTS: Fifty-seven patients were included, 33 (58 %) had a sex cord-stromal tumor (SCST) and 24 (42 %) had a germ-cell tumor (GCT). Median age, non-conservative surgery rates and DFS were lower in the GCT cohort; however, salvage chemotherapy led to a high proportion of complete responses in this group translating into a 90 % 3-year OS rate in both NEOC subtypes. The only identified risk factors statistically significant were stage and tumour relapse that associated, respectively, with DFS (HR = 8.84; 95 % CI 1.85-42) and OS (HR = 11.02; 95 % CI 1.76-68.7). CONCLUSIONS: Despite their rarity, NEOCs remain a highly curable group of neoplasm. In our series, a more conservative treatment approach in ovarian GCTs revealed comparable OS outcomes to SCST. No new risk factors that would help in patient stratification were identified.
PURPOSE:Non-epithelial ovarian cancers (NEOCs) are rare diseases. Despite their overall good prognosis, the best management and current prognostic factors remain unclear. The objective of our study was to assess the clinical and pathological features of NEOC patients treated in our institution in the last 15 years and to explore risk factors for relapse and survival. METHODS/PATIENTS: All patients with a pathological diagnosis of NEOC referred to the medical oncology department at Hospital Universitario Virgen del Rocio between 1999 and 2014 were included. Demographics, tumor characteristics, treatment procedures, and clinical follow-up were retrospectively collected. Risk factors for disease-free survival (DFS) and overall survival (OS) were assessed. RESULTS: Fifty-seven patients were included, 33 (58 %) had a sex cord-stromal tumor (SCST) and 24 (42 %) had a germ-cell tumor (GCT). Median age, non-conservative surgery rates and DFS were lower in the GCT cohort; however, salvage chemotherapy led to a high proportion of complete responses in this group translating into a 90 % 3-year OS rate in both NEOC subtypes. The only identified risk factors statistically significant were stage and tumour relapse that associated, respectively, with DFS (HR = 8.84; 95 % CI 1.85-42) and OS (HR = 11.02; 95 % CI 1.76-68.7). CONCLUSIONS: Despite their rarity, NEOCs remain a highly curable group of neoplasm. In our series, a more conservative treatment approach in ovarian GCTs revealed comparable OS outcomes to SCST. No new risk factors that would help in patient stratification were identified.
Authors: Tianhui Chen; Helja-Marja Surcel; Eva Lundin; Marjo Kaasila; Hans-Ake Lakso; Helena Schock; Rudolf Kaaks; Pentti Koskela; Kjell Grankvist; Goran Hallmans; Eero Pukkala; Anne Zeleniuch-Jacquotte; Paolo Toniolo; Matti Lehtinen; Annekatrin Lukanova Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-12-21 Impact factor: 4.254
Authors: Hannah S van Meurs; Marrije R Buist; Anneke M Westermann; Gabe S Sonke; Gemma G Kenter; Jacobus van der Velden Journal: Int J Gynecol Cancer Date: 2014-03 Impact factor: 3.437